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Hypocholesterolemia, which often accompanies infec-
tious diseases has been suggested to serve as a prog-
nostic marker in hospitalized patients. Even though
patients with chemotherapy-induced leukopenia are
at high risk of infection and mortality, only limited in-
formation is available on serum cholesterol levels in
these patients. We therefore measured serum choles-
terol levels in 17 patients with hematological malig-
nancies during chemotherapy-induced neutropenia
and correlated it with clinical outcome. Patients with
fever (>38.5 °C) showed a significant decrease in
serum cholesterol levels within 24 hours. Eight days
after onset of the fever non-survivors had significantly
lower serum cholesterol levels (median 2.09 mmol/l,
range 0.49–2.79, n=6) compared to survivors (median
3.23 mmol/l, range 1.68–4.86, n=11). Cholesterol levels
in survivors returned to baseline levels at the time of
discharge from the hospital. At the onset of fever,
serum levels of inflammatory cytokines interleukin-6,
tumor necrosis factor (TNF) and soluble TNF receptors
p55 and p75 were elevated in all patients, but only TNF
and TNF receptor p75 levels were significantly differ-
ent in survivors and non-survivors. 
Our data suggest that a decrease in serum choles-
terol levels is a prognostic marker in neutropenic pa-
tients with fever. Release of inflammatory cytokines
may in part be responsible for hypocholesterolemia in
these patients. Clin Chem Lab Med 2002; 40(3):304–307
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Introduction
A reduction in serum cholesterol levels during the
acute phase response to various conditions such as in-
fection (1–3), surgery (4), burn injury (5), sepsis and
multiorgan failure (6) has been described in humans.
The degree of hypocholesterolemia under these condi-
tions may reflect the severity of disease. In addition,
numerous recent studies indicate that low cholesterol
levels are associated with increased mortality (6–8). In
a large population of hospitalized patients prognostic
value of serum cholesterol has been reported irrespec-
tive of the underlying disease (9).
Patients with chemotherapy-induced neutropenia
are at high risk of bacterial infectious disease and fre-
quently develop fever which may lead to mortality (10).
Even though cytokine levels were elevated in these pa-
tients and increased interleukin-6 (IL-6) levels deter-
mined the mortality (11), no data on serum cholesterol
levels are available. In order to examine the prognostic
value of cholesterol concentration, we measured its
serum levels in neutropenic patients at the time of on-
set of fever in response to infection and correlated
these levels with clinical outcome. Although the under-
lying mechanism for low serum cholesterol levels in in-
flammatory conditions is still unclear, studies in exper-
imental animals suggest that cytokines which are
released during inflammation modulate lipoprotein
metabolism. It has also been reported that infusion of
IL-1 and tumor necrosis factor (TNF) (12–14) in experi-
mental animals, as well as TNF (15), IL-2 (16), IL-6 (17)
in cancer patients, diminishes plasma cholesterol lev-
els. This suggests that cytokines may in part be re-
sponsible for the hypocholesterolemia. We therefore
measured serum levels of IL-6, TNF and soluble TNF re-
ceptors (sTNF-R) in order to establish whether circulat-
ing levels of these proinflammatory cytokines correlate
with serum cholesterol levels.
Patients, Materials and Methods
Patients and blood sampling
Patients with the following oncological diagnoses were in-
cluded in the study: 11 with acute myeloid leukemia, 2 with
acute lymphocytic leukemia, 2 with chronic myeloid leukemia,
1 with non-Hodgkin lymphoma (NHL) and 1 with testicular
cancer. All patients undergoing intensive chemotherapy de-
veloped severe leukopenia (white blood count (WBC)
<1×109/l). Clinical course was followed by daily monitoring of
fever, the signs of infection (e.g. blood cultures), medication
(antibiotics, transfusion) and clinical chemistry parameters
(WBC, hemoglobin and C-reactive protein (CRP)). Patients
were included in the study at the onset of fever >38.5 °C which
was unrelated to changes in transfusion or drug therapy and
were followed for 1 week. Cholesterol was measured at the
onset of fever and subsequently on day 2, 4, 8 and at dis-
charge. Cholesterol values prior to chemotherapy were ob-
tained from hospital charts. Aliquots of serum obtained at the
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onset of fever were stored at –70 °C for the measurement of
cytokines. In addition, blood samples were collected from six
healthy volunteers who showed no signs of fever or infection
and had normal WBC.
Analytical techniques
Serum levels of cholesterol and triglycerides were measured
with Hitachi automated system (Boehringer Mannheim,
Mannheim, Germany). Serum TNF and IL-6 levels were mea-
sured with a commercial enzyme-linked immunosorbent as-
say (Biosource Europe, Nivelles, Belgium). Both assays have a
detection limit of <3 pg/ml. sTNF-R p55 and p75 were mea-
sured automatically on CobasCore with enzyme-linked
immunobinding assays (Hoffmann La Roche Ltd., Basel
Switzerland). The receptor assay has a detection limit of 100
pg/ml and is not affected by the presence of free or unbound
TNF at a concentration below 10 ng/ml (18). 
Statistics
Values for lipid and cytokine measurements are given as me-
dian and range. Statistical significance was calculated using
Mann-Whitney-Wilcoxon-test test and a p-value <0.05 was
considered significant. 
Results
Eleven out of 17 patients included in this study showed
positive blood cultures. Pathogens included Staphylo-
coccus aureus (n=3), Streptococcus spp (n=4), Entero-
coccus faecalis (n=1), Pseudomonas aeruginosa (n=1)
and Candida albicans (n=2). In the remaining six pa-
tients blood cultures were negative. Three of these pa-
tients developed clinical and radiological signs of bilat-
eral pneumonia without the presence of bacterial or
fungal pathogens either at the time of first symptoms
or during ventilation. In the remaining three patients
fever was classified as fever of unknown origin (FUO)
(Table 1).
Table 1 Characteristics of patients enrolled in the study.
No Underlying disease Underlying cause of fever Pathogen Outcome
1 AML FUO – Survived
2 AML Septicopyaemia Candida albicans Died
3 NHL Sepsis Streptococcus mitis Died
4 AML Pneumonia – Died
5 Testicular cancer Bacteremia Enterococcus faecalis Survived
6 AML Bacteremia Streptococcus mitis Survived
7 AML Bacteremia Streptococcus mitis Survived
8 ALL Pneumonia Staphylococcus aureus Died
9 AML Sepsis Pseudomonas aerug. Survived
10 AML Sepsis Streptococcus pyogenes Died
11 ALL FUO – Survived
12 AML Bacteremia Staphylococcus aureus Survived
13 AML Pneumonia – Died
14 CML Septicopyaemia Candida albicans Survived
15 AML Bacteremia Staphylococcus aureus Survived
16 CML Pneumonia – Survived
17 AML FUO – Survived
AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; ALL, acute lymphocytic leukemia; 
CML, chronic myeloid leukemia; FUO, fever of unknown origin
Figure 1 Serum cholesterol levels in all patients before ther-
apy, at the onset of fever and at discharge from hospital (sur-
vivors only).  survivors,  non-survivors.
Figure 2 Mean serum cholesterol levels of survivors () and
non-survivors () during the observation period. On day 8 af-
ter the onset of fever, cholesterol levels were available from
only 16 patients because one patient died between day 4 and
8. * statistically different from non-survivors, p<0.05.
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Onset of fever during chemotherapy-induced neu-
tropenia significantly decreased median serum choles-
terol levels from 4.58 mmol/l (range 3.10–6.54) to 3.00
mmol/l (range 1.73–4.50) (Figure 1). Cholesterol levels
in all patients showed a tendency to decrease further on
the second (median 2.64 mmol/l, range 1.66–3.49) and
fourth day (median 2.59 mmol/l, range 0.49–2.79). How-
ever, these changes were statistically not significant.
Cholesterol levels in non-survivors (n=6) on day 2, 4,
and 8 were 2.20 mmol/l (range 1.66–3.18), 2.02 mmol/l
(range 1.66–3.16) and 2.10 mmol/l (range 0.49–2.79), re-
spectively. In eleven survivors cholesterol levels were
significantly higher (p<0.05) on day 2, 4 and 8 (3.13
mmol/l, range 1.76–3.49, 2.79 mmol/l, range 1.68–3.91
and 3.23 mmol/l, range 1.68–4.86; respectively) and re-
turned to nearly baseline values of 4.68 mmol/l (range
3.08–8.15) at the time of discharge (Figure 2). 
At the onset of fever, median serum levels of IL-6,
TNF and sTNF-R were significantly higher in the pa-
tients compared to healthy controls (IL-6: 230 pg/ml
(range 8–1000) vs. 3 pg/ml (range 3–11); TNF: 19 pg/ml
(range 3–84) vs. 12 pg/ml (range 8–26); sTNF-R p55: 2.6
ng/ml (range 1.4–13.4) vs. 1.8 ng/ml (range 0.8–2.4);
sTNF-R p75: 7.0 ng/ml (range 2.4–21.0) vs. 2.5 ng/ml
(range 0.9–3.4), respectively). Serum levels of cy-
tokines and CRP of survivors and non-survivors are
summarized in Table 2. Serum levels of IL-6, TNF and
sTNF-R p55 and p75 were higher in non-survivors com-
pared to survivors. However, only values for TNF and
sTNF-R p75 were statistically significant (p<0.05).
There was no significant difference in IL-6 levels be-
tween survivors and non-survivors (median 230 pg/ml
(range 8–603) and 601 pg/ml (range 122–1000), respec-
tively), even though the highest IL-6 levels (>1000
pg/ml) were observed in three out of six non-survivors.
Discussion
Neutropenic patients with fever are at high risk of mor-
tality due to infectious diseases (19). However, in many
febrile episodes no causative organism is found and
fever is classified as FUO. It is therefore necessary to
identify some additional laboratory parameters other
than CRP and cytokines which could identify those pa-
tients who are at high risk of mortality. There are only a
few studies which report that development of sudden
hypocholesterolemia in critically ill patients is associ-
ated with mortality (20). We therefore followed the
serum cholesterol and cytokine levels in neutropenic
patients. In the present study a drastic reduction in
serum cholesterol was observed in neutropenic pa-
tients with fever. In all six patients who did not survive,
a reduction in serum cholesterol persisted during their
stay in hospital. In contrast, serum cholesterol levels
were higher in survivors and returned to values similar
to those prior to the onset of fever at the time of dis-
charge from hospital. 
Previous studies have shown that not only bacterial
and viral infections (3, 21, 22) but also inflammatory
processes such as trauma (4) or autoimmune diseases
(23) are associated with low cholesterol levels. Since all
the patients in our study developed hypocholes-
terolemia, it suggests a possible common mechanism
for hypocholesterolemia in inflammatory processes. In
accordance with previous studies, we found increased
cytokine levels at the onset of fever during neutropenia
(11, 24, 25). An increase in serum TNF and its soluble
receptors at the onset of fever was accompanied by a
reduction of cholesterol, possibly due to increased re-
moval of circulating lipoproteins (18) or diminished
synthesis rates (26).
In summary, our data, even though based on a small
number of patients, indicate that serum cholesterol is a
reliable marker for prognosis and may serve as an ad-
ditional therapy control in neutropenic patients with
fever. However, it needs to be confirmed on a larger co-
hort. The association of hypocholesterolemia with in-
creased cytokine levels supports the hypothesis that
the systemic release of cytokines plays a role in lower-
ing cholesterol during inflammation. 
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